The Efficacy, Safety, and Modification of Albuminuria in Type 2 Diabetes Subjects with Renal Disease with LINAgliptin (MARLINA-T2D; ClinicalTrials.gov Identifier: NCT01792518) trial followed patients with elevated urine albumin excretion (albumin-to-creatinine ratio greater than 30 mg/g) who were treated with linagliptin. Here, ALB is linked to type 2 diabetes mellitus.